Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Arginine Vasopressin aXis as a Potential Therapeutic Target for Posterior REverSible Encephalopathy SyndromE (XPRESSE)

NCT04950270 is registered in ClinicalTrials.gov with University Hospital, Tours as lead sponsor.

NCT NCT04950270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04950270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Arginine Vasopressin aXis as a Potential Therapeutic Target for Posterior REverSible Encephalopathy SyndromE (XPRESSE)
Lead sponsor
University Hospital, Tours
Phase
Observational
Overall status
Completed
Start date
June 18, 2022
Completion date
February 26, 2024
Enrollment
24 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

posterior reversible encephalopathy syndrome